Tandem Diabetes Care Shares Rise Following FDA Clearance of Tubeless Mobi Insulin Pump
Tandem Diabetes Care (TNDM) saw its stock price surge approximately 13% following news that the U.S. Food and Drug Administration (FDA) has cleared a tubeless version of its Mobi insulin pump. The new regulatory approval includes a specialized tubeless cartridge and infusion set, expanding the device's functionality. The clearance allows Tandem to offer more flexibility to users by providing a tubeless option while maintaining compatibility with existing systems. This product expansion is expected to strengthen Tandem's position in the continuous glucose monitoring and insulin delivery market.
Tickers: $TNDM
Topics: diabetes care insulin pumps medical devices
Read the full article at Seeking Alpha
Part of the story TANDEM DIABETES CARE INC - 8-K Filing (3 articles)